BioCheetah is a Singapore-based, Agency Science Technology and Research(A*STAR)-Institute of Molecular and Cell Biology(IMCB) spin-off company. It is primarily set up to develop and commercialize non-invasive, protein-based immunodiagnostic applications. First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in IMCB by BioCheetah’s Scientific Founder (Prof. Jean-Paul Thiery) and the co-Founder/Chief Executive Officer (Dr. Kian-Chung Lee).
Products to be developed include professional use in-vitro diagnostic ELISA and Point-of-care test (POCT) kits. The kits will employ a novel multiplex urine-based biomarkers panel with high sensitivity and specificity for diagnosis and monitoring of bladder cancer.
There are several clinical trials for clinical validation of the bladder cancer diagnostic products is currently underway locally and with several hospitals worldwide.
Company Details
- Employees
- 9
- Founded
- -
- Address
- 79 Ayer Rajah Crescent, #05-09,singapore
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.biocheetah.com
- Keywords
- in-vitro diagnostics, rapid test, bladder cancer, urological cancers, POCT, Point-of-care test, ELISA.
- HQ
- SINGAPORE, Singapore
Biocheetah Pte Ltd Questions
Biocheetah Pte Ltd's website is http://www.biocheetah.com
Biocheetah Pte Ltd's LinkedIn profile is https://sg.linkedin.com/company/biocheetah-pte-ltd
Biocheetah Pte Ltd has
9 employees.
View email and phone details for 9
employees at Biocheetah Pte Ltd.
Biocheetah Pte Ltd's industry is
Biotechnology Research
Biocheetah Pte Ltd's top competitors are
Nousq Pte Ltd,
Roceso Technologies,
Sunbird Bio,
Keyreply,
Auristone Pte Ltd,
Biorithm,
Moon Technologies,
Carecam,
Quantumtx Pte Ltd,
Uromedtech Pte Ltd.
Biocheetah Pte Ltd's categories are Biotechnology Research
Biocheetah Pte Ltd's founding year is 2018
